Keenova Publishes Acthar Gel Study in Journal of Comparative Effectiveness Research

DUBLIN – Keenova Therapeutics plc announced the publication of a new manuscript detailing the use of Acthar Gel (repository corticotropin injection) for certain severe autoimmune diseases. The study, sponsored by Keenova, was a retrospective, physician-reported survey-based medical chart review that used real‑world clinical data to assess patient characteristics, treatment patterns, and physician outcomes in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) who received Acthar Gel.

The manuscript appears in the peer-reviewed Journal of Comparative Effectiveness Research. Keenova stated that real‑world evidence for Acthar Gel in RA, SLE, or DM/PM has been limited, and this publication aims to clarify how clinicians are using the drug in complex, often treatment‑refractory cases.

"These findings add to the available data evaluating Acthar Gel as an option for appropriate patients," said George J. Wan, Vice President, Evidence, Value & Outcomes at Keenova and senior author of the study.

Keenova indicates that Acthar Gel remains an option for eligible patients who have not responded to previous treatments, and the company is committed to advancing the science behind this therapeutic. The published study is titled "Acthar Gel treatment in patients with rheumatoid arthritis, systemic lupus erythematosus, or dermatomyositis/polymyositis: Analysis of physician-reported charts."

Keenova Therapeutics plc is a global healthcare company focused on therapies for diseases with limited or no treatment options.